This is an important point because at least in preclinical settings, FLT3‐mutant allelic burden and clinical status (i.e., diagnosis versus relapse samples) are predictive of the response to FLT3 inhibitors in AML [66]. This evidence concerns the gene FLT3 and acute myeloid leukemia.